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90 Poster Session Ian easily available source of stemcells for patients everywhere. The
increasing worldwide repository of CB units is improving the chan-
ces of finding a matched unit for more patients. We present our ex-
perience with UCBT as a single source of stem cells for unrelated
transplantation in these patients.
CBSearchMethods:Matched unrelated CB searches were done
for 67 pediatric pts (0–16 yrs) with malignant (MD, n 5 44) and
nonmalignant (NMD, n 5 23) disease from 1995 to 2007 in the
NY Blood Center and Netcord. The probability of finding a 5/6
CB unit with. 3.0  10 7/kg (optimal match) was calculated com-
paring the period 1995–2001 vs 2002–07.Transplant Patients and
Methods: 32 pts. (MD5 19, NMD5 13) receivedUCBT between
1996 and 2007. 12 pts with MD were standard risk (SR) for trans-
plantation (ALL CR1–2, ANLL CR1, CML CP, MDS RAEB/
RAEBt).1 pt received a 3/6, 18 a 4/6, 13 pts a 5/6 graft. Median
cell dose was 4.3  107/kg (2.6–16.3). 3 pts received a double graft.
Conditioning regimens were adapted to diagnosis. NMD received
BuCyATG. 17 MD pts and 1 NMD pt received TBI. GvHD pro-
phylaxis was CsA plus prednisone (n 5 26), mtx (n 5 2) or MMF
(n 5 4). Engraftment and EFS analysis was done for the entire
group of transplanted pts and the MDSR plus NMD subset (n 5
25). HLA match (5/6 vs others), cell dose (\4.0 vs .4.0 10 7/kg)
and year of UCBT (96–01 vs 01–07) were compared for engraft-
ment and survival in this subset. Results: An optimal matched CB
unit was found for 6/41 pts (14%) in the 1995–2001 period vs 17/
26 (65%, p . 0.001) in the 2001–2007 period. 19 transplanted pts
(61%) engrafted. TRM was 25%, MD relapse 22%. EFS was
31% with median f/u of 21 months. Subset analysis of MDSR
plus NMD pts showed engraftment of 70% and 3 yr EFS of 36%.
In this group the only prognostic factor for survival wasHLAmatch
(5/6 vs 3/6 and 4/6:Hazard Ratio 14, p\0.001).Conclusion:CB is
a good alternative for unrelated stem cell transplantation in chil-
dren. HLA matching appears to be the most important prognostic
factor given a cell dose . 3.0  10 7/kg. Increasing availability of
optimal matched CB units worldwide will make this approach fea-
sible for more patients.243
AUTOLOGOUS STEM CELL TRANSPLANTATION IN CHILDREN WITH RE-
FRACTORY OR RELAPSED HODGKIN DISEASE IN COLOMBIA
Linares, A., Abello, V., Rosales, C., Pedraza, E., Esguerra, H.J.,
Rosales, M.L. Clınica de Marly, Bogota, Colombia.
Here we report a retrospective analysis performed to evaluate the
results of autologous hematopoietic stem cell transplantation in pe-
diatric patients withHodgkinDisease (HD) in a single center in Bo-
gota, Colombia.
Nineteen patients with relapsed or refractory HD underwent au-
tologous stem cell transplantation between 1998 and 2006. 8 fe-
male/11 male, with mean age of 10.9 years (7–14). At diagnosis
patients were staged: I and IIA 10, IIB 1, IIIA 1, IIIB 4 and stage
IV 6. The response to first line therapy was: 8 patients had failure
to induction, and 6 early relapse (before 12 months). At transplan-
tation: 10 patients were in 2nd complete remission, 2 in 3th com-
plete remission and 7 were in partial remission. The conditioning
regimenwas BEAM in 14 patients and other protocols with carmus-
tine, etoposide and cyclophosphamide or melphalan in 5 patients.
With a mean 26 months of follow-up, (8–66), the 5 year OS was
73.3% and EFS of 51.9%. 8/19 patients (42%) relapsed between 3
and 48 months after transplantation, the main cause of death was
progressive disease. One patient died before day1100 with a severe
fungal infection.
This study group is too small to establish prognostic factors for
relapse after transplantation, although is important for countries
with limited resources to have data about local results. The OS
and EFS in this group are similar to results in developed countries.
Near 50% of patients with refractory or relapsed HD can be suc-
cessfully treated with high dose chemotherapy and autologous
stem cell rescue. It’s important to have a longer follow up on these
patients so we can perform analysis on prognostic factors for relapse
and survival.SOLID TUMORS
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TREATMENT OF EPSTEIN BARR VIRUS POSITIVE NASOPHARYNGEAL
CARCINOMA WITH ADOPTIVELY TRANSFERRED CYTOTOXIC T LYM-
PHOCYTES
Louis, C.U., Straathof, K., Gerken, C., Cooper-Havlik, D., Torrano, V.,
Lopez, T., Bollard, C.M., Gresik, M.V., Weiss, H., Gee, A.,
Brenner, M.K., Rooney, C.M., Heslop, H.E., Gottschalk, S. Baylor Col-
lege of Medicine, The Methodist Hospital, Texas Children’s Hospital,
Houston, TX.
Background: The strong association of nasopharyngeal carci-
noma (NPC) with Epstein-Barr virus (EBV) makes adoptive immu-
notherapy with EBV-specific cytotoxic T cells (EBV-CTL) an
attractive therapeutic option. We have evaluated the safety and ef-
ficacy of EBV-specific CTL (EBV-CTL) in two Phase I clinical tri-
als. In the first trial, EBV-CTL were given alone and in the second
trial, we aimed to enhance in vivo expansion of EBV-CTL by lym-
phodepleting patients prior to CTL infusion. For lymphodepletion
we used CD45 monoclonal antibodies (MAbs) that unlike chemo-
therapy or radiation do not result in nonspecific destruction of
the resident immune system. Study Design:The primary objective
of these Phase I clinical trials was to determine the safety of escalat-
ing doses of EBV-CTL with or without lymphodepletion in EBV-
positive NPC patients. The secondary objective was to determine
the expansion, persistence and anti-tumor effects of infused EBV-
CTL. Results: Thirty two patients with advanced-stage NPC re-
ceived autologous EBV-CTL. Patients received a median of 2
(range 1–6) doses of CTL at 2  107–2 108 cells/m2 per infusion.
CTL administration was well tolerated except for transient swelling
at known disease sites in 4 patients. Prior to CTL infusion, 8 pa-
tients were in remission, 22 had active disease, and 2 had abnormal
imaging studies of unknown significance. Seven of 8 patients in re-
mission prior to CTL infusion remain in remission 6–64 months
post CTL. For the remaining 24 patients, the best overall response
rate was 50% with 6 complete responses (CR/CRu), 2 partial re-
sponses, and 4 with stable disease during a median follow-up of 9
months (95%CI 2–16months). Of the 6 with a CR: 4 have been sus-
tained for 2–4 years, and 2 relapsed more than 2 years post CTL.
Ten patients with active disease received CD45 MAbs prior to
EBV-CTL and 8 were evaluable for immune reconstitution analy-
sis. Infusion of CD45 MAbs resulted in transient lymphopenia (re-
solved within 7 days), increased serum IL-15 levels in 6 patients, and
significant expansion of EBV-CTL within 8 weeks post-infusion in
3 patients. Conclusion: Treatment of EBV-positive NPC with
EBV-CTL appears safe and can be associated with significant
anti-tumor activity. Lymphodepletion with CD45 MAbs prior to
CTL infusion is also safe and results in expansion of adoptively
transferred CTL in a subset of patients. These encouraging results
warrant further exploration of EBV-targeted immunotherapies for
NPC.245
REGRESSION OF EXPERIMENTAL OSTEOSARCOMA AND EWING’S SAR-
COMA FOLLOWING TRANSFER OF HER2-REDIRECTED T CELLS
Ahmed, N.1, Salsman, V.S.1, Louis, C.L.1, Dishop, M.1, Weiss, H.L.1,
Kleinerman, E.S.2, Rooney, C.M.1, Heslop, H.E.1, Gottschalk, S.1,3.
1Baylor College of Medicine, Houston, TX; 2University of Texas, Hous-
ton, TX; 3Baylor College of Medicine, Houston, TX.
Background: New therapies are needed for osteosarcoma (OS)
and Ewing’s sarcoma (EWS) since the prognosis for patients with
metastatic and/or recurrent disease has not improved over the last
two decades despite aggressive multimodal therapies. For immuno-
therapies,HER2 is an attractive target since it is expressed in 40%
of OS and up to 25% of EWS.While the use of HER2 monoclonal
antibodies has been limited by low levels of HER2 expression on
sarcoma cells, we show here that T cells expressing HER2-specific
chimeric antigen receptors (CARs) have potent anti-sarcoma activ-
ity in animal models. Methods: Mitogen-activated T cells were
transduced with a retroviral vector encoding a HER2-specific
CAR with a CD28.z-signaling endodomain (HER2-T cells). We
Poster Session I 91screened 12 OS and EWS cell lines for HER2 expression by FACS
analysis and analyzed the ability of HER2-T cells to 1) proliferate,
2) produce immunostimulatory cytokines, and 3) kill HER21 tu-
mor cells in cytoxicity assays upon exposure to HER21 OS and
EWS cell lines. The in vivo function was tested in amurine intraper-
itoneal xenograft model, which allows for serial imaging by biolu-
minescence with representative OS (LM7) and EWS (TC71) cell
lines. Imaging results were confirmed by pathological examination.
Results: 10 of 12 cell lines were HER21 by FACS analysis. HER2-
T cells recognized and killed all HER21OS and EWS cell lines in
cytotoxicity assays, whereas HER2-negative tumor cells were not
killed. Coculture ofHER2-T cells withHER21 tumor cell lines re-
sulted in T-cell proliferation, and secretion of IFN-g and IL-2 in
a HER2-dependent manner. In vivo, HER2-T cells eradicated es-
tablished intraperitoneal xenografts in 80% of animals harboring
LM7 and 70% of those harboring TC71 tumors, resulting in
long-term tumor free survival of treated animals. In contrast, deliv-
ery of non-transduced T cells did not change the tumor growth pat-
tern.Conclusions:This study shows that HER2 is a target antigen
for adoptive immunotherapy of OS and EWS. HER2-redirected T
cells not only recognized and killedHER21 tumor cells ex vivo, but
also eradicated experimental xenografts in vivo. Hence, adoptive
transfer of HER2-redirected T cells may represent a promising im-
munotherapeutic approach for OS and EWS.246
OPTIMIZING IMMUNOTHERAPY IMMEDIATELY AFTER HEMATOPOIETIC
STEM CELL TRANSPLANTATION (HSCT) TO EFFECTIVELY TREAT ESTAB-
LISHED NEUROBLASTOMA
Jing, W., Yan, X., Orentas, R.J., Johnson, B.D. Medical College of Wis-
consin, Milwaukee, WI.
Based on our previous success at inducing ‘‘protective’’ immunity
to neuroblastoma immediately after syngeneic HSCT using a com-
bination of adoptive immunotherapy and tumor vaccination, we hy-
pothesized that a similar immunotherapeutic approach would be
able to effectively treat mice with established tumors. Mice bearing
established AGN2a (neuroblastoma) tumors were given lethal total
body irradiation followed by HSCT consisting of bone marrow
supplemented with 6  106 T cells. On days 2, 7, and 14 after
HSCT, mice were vaccinated with irradiated AGN2a cells that
had been genetically modified to express CD54, CD80, CD86,
and CD137L. Bioluminescent imaging and caliper measurements
were used to monitor tumor growth. Our best results – delayed tu-
mor growth in all mice and 70% tumor-free survival – were seen
when mice were given HSCT, T cells derived from tumor-vacci-
nated syngeneic donors (pre-sensitized T cells), and vaccination.
Vaccination was an important component of the immunotherapy
in these mice, as only 36% of mice given pre-sensitized T cells
only (no vaccine) survived long-term. Several of the mice given
pre-sensitized T cells without vaccination had late tumor recur-
rences, which were not observed in vaccinated mice. This may re-
flect the requirement of a vaccine-based approach for the
induction or maintenance of long-term immune memory. Mice
givenHSCT, adoptive T cell transfer from naı¨ve mice, and vaccina-
tion also showed delayed tumor growth, but tumor-free survival was
lower (33%). Overall survival correlated with the frequency of IFN-
g-producing, tumor-reactive CD81 cells in lymphoid tissues of
treated mice. Moreover, we demonstrate that mice with regressing
tumors had higher frequencies of tumor-reactive T cells in their
lymphoid tissues thanmice with progressing tumors.When specific
immune cell subsets were depleted from the adoptively transferred
T cells two important observations were made. First, CD41 T cell
depletion was found to initially benefit tumor-bearing hosts, but the
generation of anti-tumor T cell memory was inhibited. Second,
more specific depletion of CD4 1 251 cells from the adoptively
transferred T cells can result in better tumor immunity without de-
creasing anti-tumorT cell memory. In summary, our results suggest
that a multi-faceted immunotherapeutic strategy including HSCT,
T cell adoptive transfer and early post-transplant tumor vaccination
can effectively treat mice with established neuroblastoma.247
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL SUP-
PORT VERSUS STANDARD-DOSE CHEMOTHERAPY FOR HIGH-RISK
BREAST CANCER: META-ANALYSIS OF INDIVIDUAL PATIENT DATA
FROM 15 RANDOMIZED ADJUVANT TRIALS
Ueno, N.T.1, Berry, D.A.1, Johnson, M.M.1, Lei, X.1, Lopez, V.T.1,
Caputo, J.A.1, Bregni, M.2, Demirer, T.2. 1The University of Texas
MD Anderson Cancer Center, Houston, TX; 2European Group for Blood
and Marrow Transplantation Meta-Analysis Group.
Background: The role of adjuvant high-dose chemotherapy
(HDC) with autologous hematopoietic stem-cell transplantation
for primary breast cancer at high risk of recurrence (at least 4 in-
volved axillary lymph nodes) remains ill-defined. Data from individ-
ual trials have limited power to show overall or subgroup benefit for
this indication. Methods: Individual patient data from 15 known
randomized trials (HDC vs standard-dose chemotherapy [SDC])
were merged into a single database. Disease-free survival (DFS)
was defined as time from surgery to recurrence or death; breast can-
cer-specific survival (BCSS) was time from surgery to death from
breast cancer or treatment-related toxicity; and overall survival
(OS) was time from surgery to death. Cox proportional hazards re-
gression was used to compare the effect of HDC vs SDC on DFS,
BCSS, and OS adjusted for age, trial, hormone receptor (HmR) sta-
tus (positive if either estrogen or progesterone receptor was posi-
tive), and menopausal (MP) status. Subgroup analyses were by
age, HmR and MP status. Results:Median follow-up for 6,210 pa-
tients (3,118HDC, 3,092 SDC) was 6 years (range, 0–15.3); median
patient age was 46 years (range, 20–67). HmR status was positive in
46.8% of patients, negative in 23.7%, and unknown in 29.5%;
68.9% were premenopausal, 29.4% were postmenopausal, and
1.7% was unknown.
After adjusting for age, trial andMP, HDCwas found to prolong
DFS (hazard ratio [HR] 0.87; 95% confidence interval [CI] 0.81–
0.94; P 5 0.0002) but not BCSS (HR 0.93; 95% CI 0.85–1.02; P
5 0.12) or OS (HR 0.95; 95%CI 0.87–1.03; P5 0.18). After adjust-
ing for HmR in the subset for which that information was available,
HDCwas found to prolong DFS (HR 0.83; 95%CI 0.77–0.90; P\
0.0001) and had modest but significant benefits on BCSS (HR 0.88;
CI 0.79–0.97; P5 0.014) andOS (HR 0.89; 95%CI 0.81–0.98; P5
0.016) compared to SDC. For BCSS and OS, none of age, MP or
HmR had a significant interaction with treatment, yet there was
a significant age by treatment interaction for DFS, in which HDC
was better for younger rather than older patients. Conclusions:
HDC as used in these 15 randomized studies prolongs DFS in ad-
juvant breast cancer. HDC has at most a modest benefit on BCSS
and OS compared to SDC. Whether HDC has benefit in the con-
text of contemporary taxane-based regimens and targeted therapies
is unknown and may be resolved by future clinical trials.248
KIR RECEPTOR-LIGAND INCOMPATIBILITY PREDICTS SUSCEPTIBILITY
OF OSTEOSARCOMA TO NK-MEDIATED LYSIS
Delgado, D.1, Hardin, H.2, Webster, D.2, DeSantes, K.1, Shaaban, A.2.
1University of Wisconsin School of Medicine & Public Health, Madison,
WI; 2University of Wisconsin School of Medicine & Public Health, Mad-
ison, WI.
Long-term survival for pediatric patients with high-risk solid tu-
mors remains poor despite multi-modality treatment, and new ap-
proaches are needed. Although the success of KIR (Killer
Immunoglobulin-Like Receptor) incompatible, haploidentical
stem cell transplantation has been suggested in hematological ma-
lignancies in adults and children, it has not been thoroughly exam-
ined for pediatric solid tumors. In this study, we evaluated the
potential for KIR-incompatible lysis of osteosarcoma cells, in vitro.
We hypothesized that the killing of osteosarcoma cell targets could
be predicted by the degree of KIR receptor/ligand mismatch. To
test this hypothesis, healthy donor NK cells were isolated and
KIR phenotype determined by flow cytometry. Consistent with pre-
vious studies, donorNK cells exhibited a high prevalence of all three
